Related Experiment Videos
The value of permixon in benign prostatic hypertrophy
British Journal of Urology
|February 1, 1986
Summary
Permixon (160 mg twice daily) showed no significant difference compared to placebo for treating benign prostatic hypertrophy. Both groups experienced similar improvements in urinary flow rate and symptom relief.
Area of Science:
- Urology
- Pharmacology
- Clinical Trials
Background:
- Benign prostatic hypertrophy (BPH) is a common condition in aging men.
- Effective BPH treatments are crucial for improving quality of life.
Purpose of the Study:
- To compare the efficacy of Permixon versus placebo in treating BPH.
- To evaluate objective and subjective outcomes in BPH patients.
Main Methods:
- A double-blind, placebo-controlled clinical trial was conducted.
- Participants received either Permixon (160 mg twice daily) or a placebo.
- Flow rate and symptom assessments were used to measure outcomes.
Main Results:
- Both Permixon and placebo groups demonstrated significant improvements in flow rate.
- Subjective symptom assessments also showed significant improvement in both groups.
- No statistically significant difference was observed between the Permixon and placebo treatment outcomes.
Conclusions:
- Permixon did not show a significant advantage over placebo in improving BPH symptoms or flow rate.
- Further research may be needed to clarify the role of Permixon in BPH management.